- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07725770
Ten Years Follow-up After the Arthroscopic Repair of Osteochondral Lesions of the Talus Via Autologous Matrix-induced Chondrogenesis (AMIC) (AMIC10Y)
July 21, 2026 updated by: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
This clinical study evaluates the long-term, ten-year clinical and functional outcomes of patients who underwent arthroscopic repair of osteochondral lesions of the talus (OLT) using the autologous matrix-induced chondrogenesis (AMIC) technique.
Conducted at the IRCCS Ospedale Galeazzi Sant'Ambrogio in Milan, the research addresses a critical gap in current medical literature.
While the AMIC procedure is widely utilized to treat these challenging lesions, consolidated very long-term data at the ten-year mark remains scarce.
Consequently, this study aims to verify whether the positive clinical benefits previously observed in the short and medium term remain stable over time or if they undergo a significant deterioration.
The project will span a total duration of six months, analyzing a sample size of approximately 40 patients who received this specific treatment between April 2013 and April 2016.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
The target population for this investigation consists of patients treated for osteochondral defects of the talus at the IRCCS Ospedale Galeazzi Sant'Ambrogio within the specified timeframe from April 2013 to April 2016.
To be eligible for inclusion, patients must have undergone the repair procedure via the AMIC technique utilizing a specific porcine collagen I/III membrane, commercially known as Chondro-Gide.
Conversely, the study excludes individuals with irrelevant post-operative diagnoses, such as pigmented villonodular synovitis, as well as cases where it is impossible to retrieve the necessary follow-up data.The study protocol relies on the retrospective and longitudinal analysis of clinical and functional outpatient data gathered at four distinct time points.
These checkpoints consist of a pre-operative baseline assessment followed by three post-operative follow-up evaluations conducted at one year, five years, and ten years.
Throughout these intervals, patient pain levels are quantified using the Visual Analog Scale.
Functional and clinical outcomes are measured through the American Orthopaedic Foot and Ankle Score to determine overall functionality, and the 17-item Italian Foot Function Index to evaluate disability and functional limitations.
Additionally, the European Foot and Ankle Score is administered specifically at the five and ten-year follow-ups to provide further validation aligned with the most recent international standards.
Safety and procedure survival are also strictly monitored by recording all complications, clinical failures, and surgical revisions that occurred over the ten-year span.
Finally, demographic and biometric data-including age at surgery, sex, BMI, smoking habits, and lesion characteristics such as localization and volume-are gathered to perform correlation analyses.The statistical approach is designed around the primary objective of evaluating clinical parameters across the four established time points.
This will be achieved by measuring within-patient effects using a one-way repeated measures ANOVA.
The sample size calculation was performed assuming a medium effect size of Cohen's $d = 0.3$, which corresponds to $\eta^2 = 0.059$.
With a Type I error ($\alpha$) set at 0.05, a statistical power of 0.9, and a within-subject correlation of measures of 0.5, the minimum required sample size was determined to be 30 subjects.
To safely account for a potential 20% rate of patient dropouts and missing data, this requirement was increased to 38 subjects, which aligns with the planned cohort of approximately 40 patients.
All sample size calculations were executed using R software, version 4.5.2,
utilizing the pwrss package, version 1.0.0.
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy
- IRCCS Ospedale Galeazzi-Sant'Ambrogio
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients treated for OLT between April 2013 and April 2016 at the IRCCS Ospedale Galeazzi Sant'Ambrogio.
Description
Inclusion Criteria:
- Patients who underwent repair of an osteochondral defect via the AMIC® procedure utilizing a porcine collagen I/III membrane (Chondro-Gide®).
Exclusion Criteria:
- Irrelevant post-operative diagnoses (e.g., pigmented villonodular synovitis) or the inability to retrieve follow-up data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ten years follow-up after the arthroscopic repair of osteochondral lesions of the talus via autologous matrix-induced chondrogenesis (AMIC)
Time Frame: 10 years
|
Clinical Outcomes (AOFAS - VAS)
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 21, 2026
Primary Completion (Actual)
July 21, 2026
Study Completion (Estimated)
September 21, 2026
Study Registration Dates
First Submitted
July 21, 2026
First Submitted That Met QC Criteria
July 21, 2026
First Posted (Actual)
July 24, 2026
Study Record Updates
Last Update Posted (Actual)
July 24, 2026
Last Update Submitted That Met QC Criteria
July 21, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CET 261-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteochondral Defect of Talus
-
TBF Genie TissulaireTerminated
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Terminated
-
Geistlich Pharma AGWithdrawnChondral Defect | Osteochondral Lesion of Talus | MicrofractureUnited Kingdom
-
Assiut UniversityNot yet recruitingOsteochondral Lesion of Talus
-
Samsung Medical CenterUnknownOsteochondral Lesion of TalusKorea, Republic of
-
Peking University Third HospitalCompletedOsteochondral Lesions of the Talus
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruiting
-
Duke UniversityCompletedOsteochondral Lesions of TalusUnited States
-
Hyundai Bioland Co., Ltd.Medipost Co Ltd.CompletedChondral or Osteochondral Lesion of TalusKorea, Republic of
-
Ministry of Health, KuwaitNot yet recruitingOsteochondral Lesions of the Talus